Moteur de recherche d’entreprises européennes
Financement de l’UE (4 075 132 €) : Glyco-nanoparticules pour des applications avancées en nanomédecine Hor 01/10/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Glyco-nanoparticules pour des applications avancées en nanomédecine
The advance of nanomedicine requires the development of novel materials with tailored properties, controlled circulation, optimal targeting and therapeutic efficacy after administration. Nanomaterials engineered with glycans offer multiple possibilities for nanomedicine as these biomolecules when arranged on a nanomaterial surface display strong binding to specific receptors while at the same time the glyco coating can restrict unspecific interactions with proteins, helping to avoid the mononuclear phagocyte system and improved biocompatibility in vivo. The NanoCarb Network will develop novel and well-characterised nanomaterials with synthetic and native N-glycans that will be used for therapeutics and guide development of new drug delivery applications. The project will train early stage researchers at the interface of nanotechnology and glycosciences, with the overall goal of achieving a new generation of professionals in nanomedicine for a prospective career in both academia and industry. To achieve this goal a multidisciplinary consortium has been created including universities, research centres and SMEs with broad expertise ranging from nanotechnology, carbohydrate chemistry, glycoprofiling and in vitro – in vivo screening specialists. An ambitious training plan will be implemented including courses, outreach activities, participation in seminar, and workshops for the development of scientific and transferable skills.
| Accelopment Schweiz AG | ? |
| Asociacion Centro de Investigacion CRL en Biomateriales- Cic biomaGUNE | 501 810 € |
| Consiglio Nazionale Delle Ricerche | 170 701 € |
| Istituto Di Ricerche Farmacologiche Mario Negri | 522 999 € |
| Ludger Ltd. | 303 173 € |
| Midatech Ltd. | 0,00 € |
| Midatech Pharma Espana SL | 174 240 € |
| Royal College of Surgeons in Ireland | 1 278 045 € |
| Universita Degli Studi Di Milano | 261 500 € |
| University of Warwick | 606 345 € |
| Vlaamse Instelling Voor Technologisch Onderzoek N.V. | 256 320 € |
https://cordis.europa.eu/project/id/814236
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : accelopment Schweiz AG, Zurich, Suisse.